je.st
news
Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes
2014-06-13 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. New Research Initiative Seeks to Identify Unmet Needs and Address Key Gaps in the Management of Type 2 Diabetes WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of a global registry to evaluate the experiences and outcomes of approximately 20,000 patients with type 2 diabetes in real-world settings over three years. The registry is part of Mercks new global research initiative evaluating outcomes of patients with type 2 diabetes in everyday clinical practice. Language: English Contact: Media:Pam Eisele267-305-3558orKim Hamilton908-423-6831 / 908-391-0131orInvestors:Justin Holko908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: type
research
global
expanded
Category:Biotechnology and Pharmaceuticals